6 citations · 21 across the 6 of their papers we have counts for
6 papers
The Impact of US Medical Product Regulatory Complexity on Innovation: Preliminary Evidence of Interdependence, Early Acceleration, and Subsequent Inversion
Iraj Daizadeh
Is the complexity of medical product (medicines and medical devices) regulation impacting innovation in the US? If so, how? Here, this question is investigated as follows: Various…
Singular Secular Kuznets-like Period Realized Amid Industrial Transformation in US FDA Medical Devices: A Perspective on Innovation from 1976 to 2020
Iraj Daizadeh
Introduction: Since inception, the United States (US) Food and Drug Administration (FDA) has kept a robust record of regulated medical devices (MDs). Based on these data, can we ga…
Seasonal and Secular Periodicities Identified in the Dynamics of US FDA Medical Devices (1976 2020) Portends Intrinsic Industrial Transformation and Independence of Certain Crises
Iraj Daizadeh
Background: The US Food and Drug Administration (FDA) regulates medical devices (MD), which are predicated on a concoction of economic and policy forces (e.g., supply/demand, crise…
Leveraging latent persistency in United States patent and trademark applications to gain insight into the evolution of an innovation-driven economy
Iraj Daizadeh
Objective: An understanding of when one or more external factors may influence the evolution of innovation tracking indices (such as US patent and trademark applications (PTA)) is…
Trademark filings and patent application count time series are structurally near-identical and cointegrated: Implications for studies in innovation
Iraj Daizadeh
Through time series analysis, this paper empirically explores, confirms and extends the trademark/patent inter-relationship as proposed in the normative intellectual-property (IP)-…
United States FDA drug approvals are persistent and polycyclic: Insights into economic cycles, innovation dynamics, and national policy
Iraj Daizadeh
It is challenging to elucidate the effects of changes in external influences (such as economic or policy) on the rate of US drug approvals. Here, a novel approach, termed the Chron…